FindTrial
Sign In

SIGNAL - Body fluid proteome SIGnatures for persoNALised intervention to prevent cardiovascular and renal complications in diabetes

Status
Recruiting
Phases
Phase 4
Study type
Interventional
Source
EU CTIS
Registry ID
CTIS2024-518682-95-00
Enrollment
70
Registered
2025-02-09
Start date
2025-10-20
Completion date
Unknown
Last updated
2026-01-26

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Type 2 Diabetes

Brief summary

Feasibility

Detailed description

Changes in urinary albumin excretion (≥30%), changes in urinary proteomic signatures and changes in eGFR levels (≥30%)

Interventions

DRUGSEMAGLUTIDE
DRUGFINERENONE
DRUGDAPAGLIFLOZIN

Sponsors

Steno Diabetes Center Copenhagen
Lead SponsorOTHER

Eligibility

Sex/Gender
All
Age
18 Years to No maximum

Design outcomes

Primary

MeasureTime frame
Feasibility—

Secondary

MeasureTime frame
Changes in urinary albumin excretion (≥30%), changes in urinary proteomic signatures and changes in eGFR levels (≥30%)—

Countries

Denmark, Spain

Outcome results

None listed

Source: EU CTIS · Data processed: Feb 4, 2026